BRPI0906567A2 - Derivados de ureia de tetra-hidroquinoxalina, o respectivo preparo e a respectiva aplicação em terapêutica j - Google Patents

Derivados de ureia de tetra-hidroquinoxalina, o respectivo preparo e a respectiva aplicação em terapêutica j

Info

Publication number
BRPI0906567A2
BRPI0906567A2 BRPI0906567-9A BRPI0906567A BRPI0906567A2 BR PI0906567 A2 BRPI0906567 A2 BR PI0906567A2 BR PI0906567 A BRPI0906567 A BR PI0906567A BR PI0906567 A2 BRPI0906567 A2 BR PI0906567A2
Authority
BR
Brazil
Prior art keywords
preparation
urea derivatives
therapeutic application
tetrahydroquinoxaline
tetrahydroquinoxaline urea
Prior art date
Application number
BRPI0906567-9A
Other languages
English (en)
Inventor
Alain Jean Braun
Olivier Crespin
Claudie Namane
Eric Nicolai
François Pacquet
Cécile Pascal
Christophe Philippo
Olivier Venier
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0800429A external-priority patent/FR2926817B1/fr
Priority claimed from FR0804521A external-priority patent/FR2934858B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0906567A2 publication Critical patent/BRPI0906567A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0906567-9A 2008-01-28 2009-01-27 Derivados de ureia de tetra-hidroquinoxalina, o respectivo preparo e a respectiva aplicação em terapêutica j BRPI0906567A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0800429A FR2926817B1 (fr) 2008-01-28 2008-01-28 Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
FR0804521A FR2934858B1 (fr) 2008-08-08 2008-08-08 Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
PCT/FR2009/000083 WO2009112691A2 (fr) 2008-01-28 2009-01-27 Dérivés d'urée de tetrahydroquinoxaline, leur préparation et leur application en thérapeutique j

Publications (1)

Publication Number Publication Date
BRPI0906567A2 true BRPI0906567A2 (pt) 2015-07-07

Family

ID=41037885

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906567-9A BRPI0906567A2 (pt) 2008-01-28 2009-01-27 Derivados de ureia de tetra-hidroquinoxalina, o respectivo preparo e a respectiva aplicação em terapêutica j

Country Status (24)

Country Link
US (2) US8211892B2 (pt)
EP (1) EP2238126B1 (pt)
JP (1) JP2011510919A (pt)
KR (1) KR20100111308A (pt)
CN (1) CN101981026A (pt)
AR (1) AR070255A1 (pt)
AU (1) AU2009224546B2 (pt)
BR (1) BRPI0906567A2 (pt)
CA (1) CA2713367A1 (pt)
CL (1) CL2009000173A1 (pt)
CO (1) CO6290672A2 (pt)
CR (1) CR11596A (pt)
DO (1) DOP2010000230A (pt)
EA (1) EA201070895A1 (pt)
EC (1) ECSP10010368A (pt)
IL (1) IL207195A (pt)
MA (1) MA32098B1 (pt)
MX (1) MX2010008290A (pt)
NI (1) NI201000130A (pt)
PA (1) PA8813701A1 (pt)
PE (1) PE20091323A1 (pt)
TW (1) TW200936136A (pt)
UY (1) UY31616A1 (pt)
WO (1) WO2009112691A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
TW200936136A (en) * 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
FR2948370B1 (fr) * 2009-07-27 2013-04-05 Sanofi Aventis Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
FR2948369B1 (fr) * 2009-07-27 2013-04-12 Sanofi Aventis Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
TWI472331B (zh) * 2009-11-11 2015-02-11 Sumitomo Dainippon Pharma Co Ltd ８－氮雙環〔３‧２‧１〕辛烷－８－羧醯胺衍生物
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2518051A4 (en) * 2009-12-22 2013-10-16 Shionogi & Co ADAMANTANAMINE DERIVATIVE
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2604591A4 (en) 2010-08-09 2015-07-22 Shionogi & Co PROCESS FOR THE PREPARATION OF AMINOADAMANTYL CARBAMATE DERIVATIVES
KR20130102065A (ko) 2010-09-03 2013-09-16 다이닛본 스미토모 세이야꾸 가부시끼가이샤 고리형 아미드 유도체
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2836482B1 (en) * 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
JP6043767B2 (ja) * 2014-09-26 2016-12-14 株式会社アステム 番組出力装置、補助情報管理サーバ、番組と補助情報の出力方法、及びプログラム
US10117864B2 (en) * 2015-03-18 2018-11-06 Bayer Pharma Aktiengesellschaft Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
GB201818750D0 (en) * 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
CN109956958B (zh) * 2019-04-02 2020-06-16 河北合佳医药科技集团股份有限公司 一种7-氨基-3-甲氧基甲基-3-头孢烯-4-羧酸合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
GB0505541D0 (en) * 2005-03-17 2005-04-27 Novartis Ag Organic compounds
TW200811170A (en) * 2006-06-27 2008-03-01 Sanofi Aventis Urea derivatives of tropane, their preparation and their therapeutic application
TW200811158A (en) * 2006-06-27 2008-03-01 Sanofi Aventis Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application
US8222417B2 (en) * 2007-06-27 2012-07-17 Taisho Pharmaceutical Co., Ltd Compound having 11β-HSD1 inhibitory activity
WO2009020140A1 (ja) * 2007-08-06 2009-02-12 Dainippon Sumitomo Pharma Co., Ltd. アダマンチルウレア誘導体
TW200936136A (en) * 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application

Also Published As

Publication number Publication date
AU2009224546B2 (en) 2014-01-30
EP2238126B1 (fr) 2014-11-05
WO2009112691A3 (fr) 2010-01-07
US20110009391A1 (en) 2011-01-13
PA8813701A1 (es) 2009-09-17
AU2009224546A1 (en) 2009-09-17
IL207195A (en) 2013-12-31
EP2238126A2 (fr) 2010-10-13
PE20091323A1 (es) 2009-09-26
ECSP10010368A (es) 2010-08-31
EA201070895A1 (ru) 2011-04-29
KR20100111308A (ko) 2010-10-14
US8211892B2 (en) 2012-07-03
CR11596A (es) 2010-09-13
JP2011510919A (ja) 2011-04-07
CN101981026A (zh) 2011-02-23
CL2009000173A1 (es) 2010-02-12
AR070255A1 (es) 2010-03-25
US8530657B2 (en) 2013-09-10
WO2009112691A2 (fr) 2009-09-17
TW200936136A (en) 2009-09-01
NI201000130A (es) 2010-12-17
US20120245148A1 (en) 2012-09-27
MX2010008290A (es) 2010-08-18
IL207195A0 (en) 2010-12-30
MA32098B1 (fr) 2011-02-01
DOP2010000230A (es) 2010-08-31
UY31616A1 (es) 2009-08-31
CA2713367A1 (fr) 2009-09-17
CO6290672A2 (es) 2011-06-20

Similar Documents

Publication Publication Date Title
BRPI0906567A2 (pt) Derivados de ureia de tetra-hidroquinoxalina, o respectivo preparo e a respectiva aplicação em terapêutica j
BRPI0907381A2 (pt) Derivados de carboxamidas azabicíclicos, o respectivo preparo e a respectiva aplicação em terapêutica.
BRPI0810440A2 (pt) Derivados de triazolopiridina-carboxamidas e triazolopirimidina-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0810412A2 (pt) Derivados de triazolo piridina-carboxamidas e triazolo pirimidina - carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI1012857A2 (pt) derivados de ciclopenta[c]pirrol-2-carboxilatos, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0907439A2 (pt) Derivado de carboxamidas azabiciclicos, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0715199A2 (pt) derivados de n-(amino-hetero aril)-1h-indol-2-carboxamida, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
BRPI0915438A2 (pt) derivados de piridino-piridinonas, o respectivo preparo e a respectiva aplicação em terapêutica.
IL204663A0 (en) Nicotinamide derivatives, preparastion thereof and therapeutic use thereof
MX277822B (es) Derivados de urea de tropano, su preparacion y su aplicacion terapeutica.
IL209421A (en) Kionoxalindone derivatives, medicines containing them and their use
BRPI0810430A2 (pt) Derivados de triazolo piridina - carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica
ZA201002307B (en) Quinazolinedione derivatives,preparation thereof and therapeutic uses thereof
IL210869A (en) Derivatives of imidaziadiazoles, their process, preparation, uses and medications containing them
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BRPI1013553A2 (pt) derivados de nicotinamida, o respectivo preparo e a respectiva aplicação em terapêutica como anticancerígenos
BRPI0917464A2 (pt) compostos de azetidinas polissubstituídas, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0907578A2 (pt) derivados de 3-aminoalquil-1,3-di-hidro-2h-indol-2-ona, o respectivo preparo e a respectiva aplicação em terapêutica
BR112012000104A2 (pt) derivados de pirazóis, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0923875A2 (pt) Derivados de 2-piridin-2-il-pirazol-3 (2h)-ona, o respectivo preparo e a respectiva aplicação terapêutica.
ZA201107363B (en) Quinazolinedione derivatives,preparation thereof and various therapeutic uses thereof
BRPI0923182A2 (pt) derivados de 6-cicloamino-2,3-di-piridinil-imidazo[1,2-b]piridazina, o respectivo preparo e a respectivo preparo e a respectiva aplicação terapêutica
DK2240487T3 (da) Triazolopyridaziner som para-inhibitorer, fremstilling og anvendelse heraf som lægemiddel
BRPI0822054A2 (pt) Derivados de azetidinas, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0821426A2 (pt) Compostos de n-fenil-imidazol[1,2-a]piridina-2-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2363 DE 19-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.